Article
Biochemistry & Molecular Biology
Maria Chiara Gelmi, Robert M. Verdijk, Laurien E. Houtzagers, Pieter A. van der Velden, Wilma G. M. Kroes, Gregorius P. M. Luyten, T. H. Khanh Vu, Martine J. Jager
Summary: MITF is an important regulator of melanogenesis and melanocyte development. MITF loss in uveal melanoma is associated with a shift in epithelial-to-mesenchymal transition factors and increased inflammation. Low MITF expression is also related to genetic changes such as monosomy 3/BAP1 loss and 8q gain/amplification.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biotechnology & Applied Microbiology
Xuezhu Huang, Qin Yang, Lingling Xie, Sihong Lei
Summary: This experiment investigated the role of EZH2 in depression and found that EZH2 overexpression was involved in neuroinflammation. Silencing EZH2 reversed depression-like behaviors and inflammation. Furthermore, EZH2 regulated microglia polarization by targeting miR-29b-3p and MMP2 expression.
Article
Biotechnology & Applied Microbiology
JinShan Tang, Gang Duan, YunQing Wang, Bin Wang, WenBo Li, ZiQiang Zhu
Summary: Circular RNA_ANKIB1 modulates EZH2 through miR-26b-5p to accelerate chemoresistance in osteosarcoma.
Review
Oncology
Wuhan Yu, Ning Liu, Xiaogang Song, Lang Chen, Mancai Wang, Guohui Xiao, Tengfei Li, Zheyuan Wang, Youcheng Zhang
Summary: This article focuses on the value of EZH2 research in gastric cancer by examining its crucial involvement in gastric cancer progression. The article first introduces the two main functions of EZH2: histone methylation modification and DNA methylation. It then provides a detailed description of the mechanisms of EZH2 in gastric cancer-related events, and concludes with a summary of the progress in the development of EZH2 inhibitors. This review article provides researchers studying the epigenetics of gastric cancer with new research ideas to find new targets for studying the pathogenesis of gastric cancer.
Article
Chemistry, Medicinal
Bin Zhou, Beilei Wang, Fengming Zou, Husheng Mei, Qingwang Liu, Shuang Qi, Wenliang Wang, Rui Jin, Aoli Wang, Yongfei Chen, Feiyang Liu, Wenchao Wang, Jing Liu, Qingsong Liu
Summary: A novel covalent EZH2 degrader was discovered, which can reduce the expression of EZH2 in multiple types of cancer and exhibit antiproliferation activity. This study provides an opportunity for the development of new drug candidates.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Lin Xu, Jiandong Gao, Di Huang, Pinglan Lin, Dongsheng Yao, Feng Yang, Yaheng Zhang, Xuejun Yang, Ming Wu, Chaoyang Ye
Summary: Emodin delays the progression of chronic renal failure and inhibits renal tubulointerstitial fibrosis by reducing extracellular collagen deposition and inhibiting pro-fibrotic signaling pathways, through down-regulation of EZH2.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Cell & Tissue Engineering
Li Wang, Yanyan He, Wanchen Ning
Summary: The study demonstrated that EZH2 knockdown inhibited OC formation by elevating miR-101 expression through VCAM-1 suppression, ultimately attenuating periodontitis. Silencing of EZH2 or VCAM-1 also reduced the severity of periodontitis in vivo.
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
(2021)
Article
Medicine, Research & Experimental
Xiaomin Gao, Yonghan Peng, Ziyu Fang, Ling Li, Shaoxiong Ming, Hao Dong, Rui Li, Yasheng Zhu, Wei Zhang, Baoyi Zhu, Junhao Liao, Zeyu Wang, Min Liu, Weijian Li, Jianwen Zeng, Xiaofeng Gao
Summary: Inhibition of EZH2 attenuates hyperoxaluria-induced TECs injury and reduces CaOx crystal deposition by modulating the JNK/FoxO3a pathway. EZH2 may be a promising therapeutic target in TECs injury.
Article
Biotechnology & Applied Microbiology
Jingyang Zhou, Jinhui Che, Lu Xu, Weizhong Yang, Yunmei Li, Wuyuan Zhou, Shubing Zou
Summary: This study investigated the role and mechanism of miR-381 in the development and chemoresistance of HCC. It was found that EZH2 suppressed miR-381 expression, leading to increased SETDB1 expression and activation of the AKT pathway, thereby promoting hepatocarcinogenesis and chemoresistance.
Article
Oncology
Parminder Kaur, Shiv Verma, Prem Prakash Kushwaha, Sanjay Gupta
Summary: Epigenetic modifications play a crucial role in cancer pathogenesis. EZH2 is involved in gene silencing through its canonical role and also promotes carcinogenesis through its non-canonical role. NF-kB, an important molecule for survival during carcinogenesis, may crosstalk with EZH2 to promote cancer progression.
Article
Oncology
Jing Zhu, Ning Zhu, Jian Xu
Summary: The study showed that miR-101a-3p may prevent atrial fibrillation in rats by inhibiting collagen synthesis and atrial fibrosis, with EZH2 as a target.
MOLECULAR MEDICINE REPORTS
(2021)
Article
Cell Biology
Sumukh Thakar, Yash T. Katakia, Shyam Kumar Ramakrishnan, Niyati Pandya Thakkar, Syamantak Majumder
Summary: The research reveals that intermittent high glucose exposure induces endothelial inflammation, possibly through increased H3K27me3 levels, EZH2 nuclear retention, and inhibition of KLF2 and KLF4 gene expression.
Article
Medicine, Research & Experimental
Nisha Gautam, Satbir Kaur, Surender Kashyap
Summary: In this study, three SNPs (rs.2302427C>G, rs.3757441C>T, and rs.6950683T>C) of the EZH2 gene were analyzed for genetic polymorphism. The results showed that two of these SNPs have a protective role in breast cancer development, and two haplotypes were associated with a lower risk of breast cancer. Specifically, the SNP rs.2302427C>G was identified as an important prognostic biomarker for breast cancer patient survival.
ARCHIVES OF MEDICAL RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Xuwei Zheng, Xiaoyan Zhao, Zhanying Han, Kui Chen
Summary: This study reveals that down-regulated EZH2 or elevated miR-139-5p can inhibit AS progression by regulating HASMCs proliferation and apoptosis, arterial tissue oxidative stress, cell apoptosis, and inflammatory response in AS mice. This effect may be related to the down-regulation of STAT1.
Article
Oncology
Xiaxia Shao, Tao Zhao, Lei Xi, Yuhong Zhang, Jia He, Jie Zeng, Lichun Deng
Summary: The study demonstrated that the upregulation of LINC00565 and EZH2 in CRC tissues, especially in advanced stages and large tumor sizes, highlights their diagnostic value in CRC. LINC00565, predominantly located in the cytoplasm, binds with EZH2 and together they co-regulate the functions of CRC cells.
Article
Cell Biology
Tsu-Yang Chao, Theresa Kordass, Wolfram Osen, Stefan B. Eichmueller
Summary: The miRNAs miR-134-3p and miR-224-3p were found to directly interact with the SOX9 gene and inhibit its expression in breast cancer cells. These two miRNAs were down-regulated in breast cancer tissues, suggesting their potential role as tumor suppressors in breast cancer progression.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2023)
Article
Oncology
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long
Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Lucas Schneider, Christoph Wies, Eva I. Krieghoff-Henning, Tabea-Clara Bucher, Jochen S. Utikal, Dirk Schadendorf, Titus J. Brinker
Summary: In this study, the contribution of different data types in a combined classifier for predicting BRAF mutation status in melanoma was analyzed. The multimodal classifier showed improved generalisability compared to individual classifiers.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Alexander C. J. van Akkooi, Dirk Schadendorf, Alexander M. M. Eggermont
Summary: Sentinel lymph node biopsy (SLNB) was introduced in the 1990s to identify patients who may benefit from completion lymph node dissection. SLNB staging has been found to be the best for staging melanoma. Adjuvant systemic therapy and biomarkers are emerging, which might reduce the need for SLNB staging in the future.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Dermatology
Jan-Malte Placke, Delphine Mertens, Alpaslan Tasdogan, Eleftheria Chorti, Dirk Schadendorf, Selma Ugurel, Alexander Roesch, Ingo Stoffels, Joachim Klode
Summary: This study demonstrates that multispectral optoacoustic tomography (MSOT) can differentiate between benign and malignant lymphadenopathy by measuring the levels of oxyhemoglobin and deoxyhemoglobin in lymph nodes. It offers a noninvasive approach to avoid unnecessary lymph node biopsies and surgeries.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Oncology
Antonino A. A. Pane, Theresa Kordass, Agnes Hotz-Wagenblatt, Elke Dickes, Annette Kopp-Schneider, Rainer Will, Barbara Seliger, Wolfram Osen, Stefan B. B. Eichmueller
Summary: This study identified several miRNA species that can affect the susceptibility of melanoma cells to T cell-mediated killing. These miRNAs may represent attractive candidates for novel therapy approaches against melanoma and other tumors.
CLINICAL AND TRANSLATIONAL MEDICINE
(2023)
Article
Infectious Diseases
Laven Mavarani, Sarah Albayrak-Rena, Anja Potthoff, Martin Hower, Sebastian Dolff, Stefanie Sammet, Felix Maischack, Dirk Schadendorf, Boerge Schmidt, Stefan Esser
Summary: Our study evaluated the changes in weight, body-mass-index (BMI), and waist-to-hip ratio (WHR) over a 5-year follow-up in people living with HIV (PLH) compared to the general population. The results showed that PLH had greater increases in weight and BMI after 5 years, but lower WHR change compared to the general population.
Article
Oncology
Filippo de Braud, Christophe Dooms, Rebecca S. Heist, Celeste Lebbe, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Rutkowski, Juergen Wolf, Paolo A. Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith McKean, Eva Munoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuan-Mai Couillebault, Helen Evans, Catarina D. Campbell, Sumit Basu, Michele Moschetta, Adil Daud
Summary: This study explores a targeted therapy for treating NRAS-mutant melanoma, showing promising antitumor activity in patients with the use of LXH254 and trametinib in combination.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Paolo Antonio Ascierto, Evan J. Lipson, Reinhard Dummer, James Larkin, Georgina V. Long, Rachel E. Sanborn, Vanna Chiarion-Sileni, Brigitte Dreno, Stephane Dalle, Dirk Schadendorf, Margaret K. Callahan, Marta Nyakas, Victoria Atkinson, Carlos Alberto Gomez-Roca, Naoya Yamazaki, Hussein A. Tawbi, Naomey Sarkis, Deepti Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, Jean-Jacques Grob
Summary: Preliminary research shows that nivolumab and relatlimab have better efficacy in treating advanced melanoma patients who have previously received anti-PD-(L)1 treatment. The RELATIVITY-047 trial demonstrated that nivolumab and relatlimab, compared to nivolumab alone, significantly improved progression-free survival in previously untreated advanced melanoma patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Jean-Jacques Grob, Andriy Moshyk, Jennifer Lord-Bessen, Melissa Hamilton, Shien Guo, Ling Shi, Sarah Keidel, Georgina Long
Summary: The RELATIVITY-047 trial demonstrates that the fixed-dose combination of nivolumab plus relatlimab improves progression-free survival in patients with advanced melanoma while maintaining stable health-related quality of life. Although the combination treatment is associated with a higher incidence of severe adverse events, patients' discomfort with these events is low, supporting NIVO + RELA as a first-line treatment option.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Philipp Jansen, Daniel Otero Baguer, Nicole Duschner, Jean Le'Clerc Arrastia, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Joerg Schaller, Klaus Georg Griewank
Summary: In this study, a deep learning method was used to analyze histological tissue sections of melanoma patients, enabling accurate detection of lymph node metastasis and providing valuable reference for pathologists. The method was able to identify the size and classify the tumor, which is of great significance for prognosis assessment and treatment planning.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Carola Berking, Elisabeth Livingstone, Dirk Debus, Carmen Loquai, Michael Weichenthal, Ulrike Leiter, Felix Kiecker, Peter Mohr, Thomas K. Eigentler, Janina Remy, Katharina Schober, Markus V. Heppt, Imke von Wasielewski, Dirk Schadendorf, Ralf Gutzmer
Summary: The outcome of advanced melanoma patients has greatly improved over the past 15 years. Targeted therapies blocking BRAF or inhibiting immune checkpoints have shown significant efficacy in improving overall survival. The COMBI-r study confirms the efficacy of dabrafenib plus trametinib in routine clinical practice and provides additional data in patients with brain metastases or previous treatments.
Article
Oncology
Esmee P. Hoefsmit, Franziska Vollmy, Elisa A. Rozeman, Irene L. M. Reijers, Judith M. Versluis, Liesbeth Hoekman, Alexander C. J. van Akkooi, Georgina Long, Dirk Schadendorf, Reinhard Dummer, Maarten Altelaar, Christian U. Blank
Summary: Taking into account the higher response rates of neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma compared to stage IV disease, researchers hypothesized that systemic immune suppression may be responsible for lower response rates and disease recurrence. Through proteomic profiling, they found that the protein LRG1 is associated with worse prognosis and can serve as a biomarker for identifying high-risk patients and as a potential target for neoadjuvant ICB therapy.
CANCER RESEARCH COMMUNICATIONS
(2023)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Paolo A. Ascierto, Reinhard Dummer, Helen J. Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T. Flaherty
Summary: The purpose of this study was to evaluate the efficacy and safety of encorafenib alone or in combination with binimetinib for the treatment of advanced BRAF(V600)-mutant melanoma. The results showed that the combination of encorafenib and binimetinib improved progression-free survival and overall response rate, and had better tolerability compared to encorafenib alone.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.